Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study
Philadelphia, Pennsylvania; Los Angeles, California; Salt Lake City, Utah; Williamsville, New York; Dallas, Texas; Portland, Oregon; Norfolk, Virginia; and Bethesda, Maryland
J AM ACAD DERMATOL OCTOBER 2019
Background: There are limited data about the impact of narrowband ultraviolet B phototherapy on patient-reported measures of health-related quality of life.
Objective: To evaluate the impact of adalimumab and phototherapy on health-related quality of life.
Methods: We examined patient-reported outcomes from a multicenter, randomized, placebo-controlled trial (ClinicalTrials.gov no. NCT01553058). The Dermatology Life Quality Index and EQ-5D-3L were evaluated every 4 weeks.
Conclusion: Phototherapy and adalimumab both improve skin-related quality of life and overall health-related quality of life compared with placebo in patients with psoriasis; however, patients treated with phototherapy achieved more improvement in overall health-related quality of life compared with patients treated with adalimumab.